D.E. Shaw & Co
BIOT

D.E. Shaw & Co’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

D.E. Shaw & Co’s Portfolio BIOT Stock Details BIOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-929,085
Closed -$9.38M – 5188
2022
Q4 		$9.38M Hold
929,085
– – 0.01% 1496
2022
Q3 		$9.22M Hold
929,085
– – 0.01% 1427
2022
Q2 		$9.2M Hold
929,085
– – 0.01% 1467
2022
Q1 		$9.15M Hold
929,085
– – 0.01% 1672
2021
Q4 		$9.14M Buy
929,085
+399,255
+75% +$3.92M 0.01% 1741
2021
Q3 		$5.16M Buy
529,830
+346,182
+189% +$3.36M ﹤0.01% 2076
2021
Q2 		$1.78M Buy
+183,648
New +$1.78M ﹤0.01% 3063

D.E. Shaw & Co's BIOT Position: Q1 2023 in Review

D.E. Shaw & Co sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 929,085 shares — an estimated $9.38M sold.

D.E. Shaw & Co first reported a position in BIOT in Q2 2021 and held it in 7 quarters. The position peaked at $9.38M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

  • D.E. Shaw & Co reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
  • D.E. Shaw & Co sold 929,085 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $9.38M.
  • D.E. Shaw & Co first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
  • D.E. Shaw & Co's Biotech Acquisition Company Class A Ordinary Shares position peaked at $9.38M in Q4 2022.
  • 0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on D.E. Shaw & Co's 13F filing for Q1 2023, filed 15 May 2023.